Our research demonstrates that the abundance of TR CD8 + TILs is a prognostic marker for neoadjuvant immunotherapy in pancreatic cancer, and that TCR-T with a combination of multiple TR TCRs has a significantly higher tumor-killing ability than a single type of TCR-T. This evidence concerns the gene CD8A and familial pancreatic carcinoma.